阿替利珠单抗联合顺铂化疗治疗非小细胞肺癌的预后分析

Prognostic analysis of atezolizumab combined with cisplatin chemotherapy in the treatment of non-small cell lung cancer

目的探讨阿替利珠单抗联合顺铂化疗治疗非小细胞肺癌的预后。方法回顾性选取2020年1—10月湖南省脑科医院治疗的非小细胞肺癌患者98例作为研究对象,根据不同治疗方案分别纳入干预组(n=47)和对照组(n=51),对照组接受顺铂化疗,干预组接受阿替利珠单抗联合顺铂化疗,对两组的预后情况进行比较。结果干预组总缓解率高于对照组,差异有统计学意义(P<0.05)。干预组不良反应发生率与对照组比较,差异无统计学意义(P>0.05)。治疗后,干预组卡氏评分(KPS)、生存质量(FACT-L)评分均高于对照组,差异有统计学意义(P<0.05)。结论阿替利珠单抗联合顺铂化疗治疗非小细胞肺癌的疗效显著,不良反应发生较少,且可有效提高患者的生存质量。

Objective To explore the prognosis of patients with non-small cell lung cancer(NSCLC)treated with atezolizumab combined with cisplatin chemotherapy.Methods A total of 98 patients with NSCLC who were treated in Brain Hospital of Hunan from January 2020 to October 2020 were selected retrospectively,and they were divided into the intervention group(n=47)and the control group(n=51)according to different treatment schemes.The control group received cisplatin chemotherapy,while the intervention group received atezolizumab combined with cisplatin chemotherapy.The prognosis of the two groups was compared.Results The total remission rate in the intervention group was higher than that in the control group,with statistically significant difference(P<0.05).There was no significant difference in the incidence of adverse reactions between intervention group and control group(P>0.05).After treatment,the KPS and FACT-L scores of the intervention group were higher than those of the control group,and the difference was statistically significant(P<0.05).Conclusion Atezolizumab combined with cisplatin chemotherapy is effective in the treatment of NSCLC with fewer adverse reactions,which can effectively improve the quality of life of patients.